New knowledge in genetics and inflammatory bowel disease. are there any practical applications?;Nuevos conocimientos en genética y enfermedad inflamatoria intestinal. ¿alguna utilidad práctica?

Gastroenterologia y Hepatologia

Volumn 34, Issue 9, 2011, Pages 591-598

  Iborra, Marisa ^a,b   Beltrán, Belén ^a,b   Nos, Pilar ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; ENTERITIS; GENETICS; PROFESSIONAL KNOWLEDGE;

HUMANS; INFLAMMATORY BOWEL DISEASES; MICRORNAS;

EID: 82655168813     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.08.003     Document Type: Editorial

References (81)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
2. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
3. Packey C.D., Sartor R.B. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008, 263:597-606.
4. Orholm M., Munkholm P., Langholz E., Nielsen O.H., Sorensen T.I., Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324:84-88.
5. Lowe A.M., Roy P.O., B-Poulin M., Michel P., Bitton A., St-Onge L., et al. Epidemiology of Crohn's disease in Québec, Canada. Inflamm Bowel Dis 2009, 15:429-435.
6. Brant S.R. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011, 17:1-5.
7. Ahmad T., Tamboli C.P., Jewell D., Colombel J.F. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004, 126:1533-1549.
8. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
9. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
10. Thompson A.I., Lees C.W. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011, 17:831-848.
11. Cho J.H., Brant S.R. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011, 140:1704-1712.
12. Lees C.W., Barrett J.C., Parkes M., Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011.
13. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
14. Karayiannakis A.J., Syrigos K.N., Efstathiou J., Valizadeh A., Noda M., Playford R.J., et al. Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. J Pathol 1998, 185:413-418.
15. Azarschab P., Porschen R., Gregor M., Blin N., Holzmann K. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer 2002, 35:121-126.
16. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444.
17. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008, 226:205-218.
18. Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schaffer A.A., Noyan F., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361:2033-2045.
19. Louis E., Libioulle C., Reenaers C., Belaiche J., Georges M. Genetics of ulcerative colitis: the come-back of interleukin 10. Gut 2009, 58:1173-1176.
20. Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473-1482.
21. Schreiber S., Fedorak R.N., Nielsen O.H., Wild G., Williams C.N., Nikolaus S., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000, 119:1461-1472.
22. Lesage S., Zouali H., Cezard J.P., Colombel J.F., Belaiche J., Almer S., et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002, 70:845-857.
23. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W.J., McCormick B.A., Podolsky D.K. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124:993-1000.
24. Vermeire S., Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun 2005, 6:637-645.
25. Arijs I., Li K., Toedter G., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58:1612-1619.
26. Buning C., Genschel J., Buhner S., Kruger S., Kling K., Dignass A., et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004, 19:1073-1078.
27. Economou M., Trikalinos T.A., Loizou K.T., Tsianos E.V., Ioannidis J.P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004, 99:2393-2404.
28. Dassopoulos T., Nguyen G.C., Talor M.V., Datta L.W., Isaacs K.L., Lewis J.D., et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am J Gastroenterol 2011, 105:378-386.
29. Inoue N., Tamura K., Kinouchi Y., Fukuda Y., Takahashi S., Ogura Y., et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002, 123:86-91.
30. Yamazaki K., Takazoe M., Tanaka T., Kazumori T., Nakamura Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 2002, 47:469-472.
31. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2011, 42:1118-1125.
32. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
33. Levine B., Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol 2007, 7:767-777.
34. Cadwell K., Liu J.Y., Brown S.L., Miyoshi H., Loh J., Lennerz J.K., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456:259-263.
35. Cadwell K., Patel K.K., Maloney N.S., Liu T.C., Ng A.C., Storer C.E., et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2011, 141:1135-1145.
36. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2011, 16:90-97.
37. Travassos L.H., Carneiro L.A., Ramjeet M., Hussey S., Kim Y.G., Magalhaes J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2011, 11:55-62.
38. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
39. Parkes M., Barrett J.C., Prescott N.J., Tremelling M., Anderson C.A., Fisher S.A., et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007, 39:830-832.
40. Leshed A., Somasundaram R., de Haar C., van der Woude C.J., Braat H., Peppelenbosch M.P. Role of defective autophagia and the intestinal flora in Crohn disease. Self Nonself 2011, 1:323-327.
41. McCarroll S.A., Huett A., Kuballa P., Chilewski S.D., Landry A., Goyette P., et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008, 40:1107-1112.
42. Skipper L., Li Y., Bonnard C., Pavanni R., Yih Y., Chua E., et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 2005, 14:3549-3556.
43. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 2011, 107:9879-9884.
44. Wang K., Zhang H., Kugathasan S., Annese V., Bradfield J.P., Russell R.K., et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 2009, 84:399-405.
45. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
46. Burton P.R., Clayton D.G., Cardon L.R., Craddock N., Deloukas P., Duncanson A., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
47. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580-592.
48. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
49. Sedivy J.M., Banumathy G., Adams P.D. Aging by epigenetics--a consequence of chromatin damage?. Exp Cell Res 2008, 314:1909-1917.
50. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
51. Yung R.L., Julius A. Epigenetics, aging, and autoimmunity. Autoimmunity 2008, 41:329-335.
52. Holliday R. Epigenetics: a historical overview. Epigenetics 2006, 1:76-80.
53. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
54. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
55. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
56. Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., Enright A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34:D140-D144.
57. Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005, 37:766-770.
58. Asirvatham A.J., Magner W.J., Tomasi T.B. miRNA regulation of cytokine genes. Cytokine 2009, 45:58-69.
59. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4:e6229.
60. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
61. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
62. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
63. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103:12481-12486.
64. O'Connell R.M., Rao D.S., Chaudhuri A.A., Boldin M.P., Taganov K.D., Nicoll J., et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008, 205:585-594.
65. Bazzoni F., Rossato M., Fabbri M., Gaudiosi D., Mirolo M., Mori L., et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A 2009, 106:5282-5287.
66. Iborra M., Bernuzzi F., Invernizzi P., Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2011, [Epub ahead of print].
67. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009, 8:520-524.
68. Pauley K.M., Cha S., Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009, 32:189-194.
69. Sonkoly E., Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med 2009, 13:24-38.
70. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2011, 10:111-122.
71. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2011, 34:J207-J219.
72. Wu F., Zikusoka M., Trindade A., Dassopoulos T., Harris M.L., Bayless T.M., et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008, 135:1624-1635. e24.
73. Takagi T., Naito Y., Mizushima K., Hirata I., Yagi N., Tomatsuri N., et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 2011, 25(Suppl 1):S129-S133.
74. Fasseu M., Tréton X., Guichard C., Pedruzzi E., Cazals-Hatem D., Richard C., et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One 2010, 5. pii: e13160.
75. Wu F., Zhang S., Dassopoulos T., Harris M.L., Bayless T.M., Meltzer S.J., et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2011, 16:1729-1738.
76. Wu F., Guo N.J., Tian H., Marohn M., Gearhart S., Bayless T.M., et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2011, 17:241-250.
77. Dalal S.R., Kwon J.H. The Role of MicroRNA in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 2011, 6:714-722.
78. Pekow J.R., Kwon J.H MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2011, 18. [Epub ahead of print]. 10.1002/ibd.21691.
79. Padgett K.A., Lan R.Y., Leung P.C., Lleo A., Dawson K., Pfeiff J., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009, 32:246-253.
80. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
81. Olaru A.V., Selaru F.M., Mori Y., Vazquez C., David S., Paun B., et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis 2011, 17:221-231.